Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,911.00-1.33%ETH$2,404.67-3.01%GOLD$4,387.10+1.25%OIL$103.69-2.02%
Smart Investors Daily
CM

NASDAQ · CMND

Clearmind Medicine Inc.

Healthcare · Biotechnology

$0.86

Down-$0.08 (-8.44%)

Updated Sep 16, 2026, 11:23 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
387.88K
P/E ratio
-0.07
Dividend yield
0.00%
52-week range
$0.52 – $6.03
Volume
168.73K
Avg. volume
13.42M

Price performance

CMND price history

1M range · 20 trading sessions · Daily adjusted prices

CMND closed at $0.86 after 20 trading sessions, down 55.90% for the selected period.

Last close
$0.86
Period change
-55.90%
Period low
$0.86
Period high
$1.96
Daily close
View OHLC price history
CMND OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$0.918$0.9329$0.8333$0.8643168.73K
Sep 14, 2026$0.94$0.9698$0.9173$0.944168.85K
Sep 11, 2026$0.9998$1.06$0.95$0.9667288.31K
Sep 10, 2026$1.00$1.045$0.9803$0.9816102.84K
Sep 9, 2026$1.07$1.11$1.00$1.06336.83K
Sep 8, 2026$1.15$1.15$0.9199$1.033.12M
Sep 4, 2026$1.495$1.555$1.16$1.1615.51M
Sep 3, 2026$1.81$1.84$1.70$1.7060.08K
Sep 2, 2026$1.85$1.8699$1.79$1.8547.22K
Sep 1, 2026$1.93$1.93$1.76$1.83221.47K
Aug 31, 2026$1.82$2.10$1.81$1.94718.96K
Aug 28, 2026$1.82$1.8399$1.73$1.7624.79K
Aug 27, 2026$1.85$1.85$1.75$1.8165.47K
Aug 26, 2026$1.68$1.74$1.66$1.7237.89K
Aug 25, 2026$1.6897$1.75$1.65$1.7142.81K
Aug 24, 2026$1.75$1.75$1.61$1.6897.17K
Aug 21, 2026$1.74$1.835$1.74$1.7447.14K
Aug 20, 2026$1.93$1.93$1.70$1.73109.39K
Aug 19, 2026$1.96$1.96$1.88$1.9163.44K
Aug 18, 2026$1.88$2.31$1.84$1.96835.58K

Latest CMND news

The latest Smart Investors Daily articles mentioning CMND.

Stock researchCompany · Overview

CMND research

Overview

Company profile and research snapshot.

Company profile

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 11, 2026

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the enrollment of the first patients with Alcohol Use Disorder (“AUD”) in its ongoing clinical trial evaluating CMND-100, the Company’s proprietary

Yahoo · Sep 8, 2026

Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results

Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company” or “Clearmind”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced that the Yale University’s IRB has approved the initiation of patient recruitment for Parts B and C of its Phase I/II clinical trial

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By